should there have been an announcement today? , page-4

All, I'm trying to further my knowledge and understand PAT-SM6's place in the market.

Just reading up a little on Daratumumab after that article mentions it. These are the results of the Phase 1/2 study for Daratumumab:

"To date, the study has enrolled 29 relapsed or refractory myeloma patients."
"At the most recent follow-up, researchers found that 24 percent of patients have achieved a partial response. An additional 14 percent of patients have achieved a minimal response, and 24 percent of patients have stable disease."

So based on that I assume their results were significantly better than PABs?

On the upside we don't seem to have any negative side effects and have a very low toxicity profile. Does this mean the most likely (or only) way forward for PAT-SM6 is in combination with another treatment? From the results it seems PAT-SM6 may make other drugs more effective but would not be a primary/solitary treatment option like others?